Medicine
Amvuttra 25 mg/0.5 mL injection
Amvuttra 25 mg/0.5 mL injection is a prescription medicine containing Vutrisiran for subcutaneous use, marketed by Alnylam Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Do not freeze. Store at 2°C to 30°C (36°F to 86°F) in the original carton…
Key facts
- Active ingredient (INN)
- Vutrisiran
- Brand
- Amvuttra
- Strength
- 25 mg/0.5 mL
- Dosage form
- Injection
- Route
- Subcutaneous
- Packs
- 1 syringe of 0.5 mL
- Marketing authorisation holder
- Alnylam Pharmaceuticals
- Manufacturer
- Alnylam Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Do not freeze. Store at 2°C to 30°C (36°F to 86°F) in the original carton, until ready for use.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- N07XX18 Vutrisiran
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 13 June 2022
- Identifiers
- RxCUI 2604788, 2604794DailyMed set ID 8db0facb-81b6-4006-9239-27dc6409c5d3NDC 71336-1003Application NDA215515
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 syringe, glass in 1 carton / .5 mL in 1 syringe, glass | 71336-1003-1 | Alnylam Pharmaceuticals | 13 June 2022 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Vutrisiran is a small interfering RNA indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality, among other approved uses. MedsAcross supplies Vutrisiran for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about VutrisiranFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- AMVUTTRA prescribing information (Alnylam Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
- Amvuttra: European public assessment report (EPAR) · European Medicines Agency
Need Amvuttra 25 mg/0.5 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.